Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07646171
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)Tel-Aviv Sourasky Medical CenterRecruiting
NCT07646171Recruiting
—
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+)...Tel-Aviv Sourasky Medical...
NCT07644104
Efficacy and Safety of the Visual Bronchial Blocker for Lung Isolation SurgeryZhejiang UniversityNot Yet RecruitingNot Applicable
NCT07644104Not Yet Recruiting
Not Applicable
Efficacy and Safety of the Visual Bronchial Blocker for Lung Isolation SurgeryZhejiang University
NCT07645339
Efficacy and Safety of a Topical Botanical Extract Formulation for Skin Barrier RepairL'OrealActive Not RecruitingNot Applicable
NCT07645339Active Not Recruiting
Not Applicable
Efficacy and Safety of a Topical Botanical Extract Formulation for Skin Barrier...L'Oreal
NCT07645144
FES-assisted Gait Training for Incomplete Spinal Cord InjuryStichting ReadeEnrolling By InvitationNot Applicable
NCT07645144Enrolling By Invitation
Not Applicable
FES-assisted Gait Training for Incomplete Spinal Cord InjuryStichting Reade
NCT07646262
Gluten-Free vs Mediterranean Diet in Rheumatoid ArthritisHasan Kalyoncu UniversityRecruitingNot Applicable
NCT07646262Recruiting
Not Applicable
Gluten-Free vs Mediterranean Diet in Rheumatoid ArthritisHasan Kalyoncu University
NCT07644481
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete RemissionInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet RecruitingNot Applicable
NCT07644481Not Yet Recruiting
Not Applicable
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melpha...Institute of Hematology &...
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07646054
Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers23andMe, Inc.Not Yet RecruitingNot Applicable
NCT07646054Not Yet Recruiting
Not Applicable
Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers23andMe, Inc.
NCT07645521
Trans-nasal Sphenopalatine Ganglion Block for Prevention of Emergence Agitation Following Functional Endoscopic Sinus SurgeryMansoura UniversityCompletedNot Applicable
NCT07645521Completed
Not Applicable
Trans-nasal Sphenopalatine Ganglion Block for Prevention of Emergence Agitation...Mansoura University
NCT07645079
Automated Insulin Delivery Versus Daily Injections for Hospital Diabetes CareSteno Diabetes Center CopenhagenNot Yet RecruitingNot Applicable
NCT07645079Not Yet Recruiting
Not Applicable
Automated Insulin Delivery Versus Daily Injections for Hospital Diabetes CareSteno Diabetes Center Cop...
NCT07644988
Comparing Two Muscle Relaxation Techniques for Neck PainUniversity of FaisalabadActive Not RecruitingNot Applicable
NCT07644988Active Not Recruiting
Not Applicable
Comparing Two Muscle Relaxation Techniques for Neck PainUniversity of Faisalabad
NCT07644442
Study on [14C]HMPL-453（FGFR Inhibitor） in Healthy Chinese Adult Male SubjectsHutchmedCompletedPhase 1
NCT07644442Completed
Phase 1
Study on [14C]HMPL-453（FGFR Inhibitor） in Healthy Chinese Adult Male SubjectsHutchmed
NCT07646080
Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma ProtuberansYanjie Zhang, MDNot Yet RecruitingPhase 2
NCT07646080Not Yet Recruiting
Phase 2
Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemothera...Yanjie Zhang, MD
NCT07643805
Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCLThe First Affiliated Hospital with Nanjing Medical UniversityNot Yet RecruitingPhase 1
NCT07643805Not Yet Recruiting
Phase 1
Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Pat...The First Affiliated Hosp...
NCT07645872
Clinical Data Collection of Patients Treated With High Intensity Focused Ultrasound (HIFU) by the Focal One for Their Prostate Cancer.EDAP TMS S.A.Recruiting
NCT07645872Recruiting
—
Clinical Data Collection of Patients Treated With High Intensity Focused Ultraso...EDAP TMS S.A.
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07646470
Effects of Chronic Non-invasive Vagus Nerve Stimulation in an Asplenic Individual Suffering From Rheumatoid ArthritisOsteoflow Health ClinicCompletedNot Applicable
NCT07646470Completed
Not Applicable
Effects of Chronic Non-invasive Vagus Nerve Stimulation in an Asplenic Individua...Osteoflow Health Clinic
NCT07644533
Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced CancerAffiliated Hospital of Qinghai UniversityNot Yet RecruitingNot Applicable
NCT07644533Not Yet Recruiting
Not Applicable
Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in...Affiliated Hospital of Qi...
NCT07644234
Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patients With Acute Ischemic StrokeSichuan Provincial People's HospitalNot Yet RecruitingPhase 4
NCT07644234Not Yet Recruiting
Phase 4
Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patie...Sichuan Provincial People...
Result Breakdown
Not yet recruiting9 (45%)
Recruiting5 (25%)
Completed3 (15%)
Active, not recruiting2 (10%)
Enrolling by invitation1 (5%)
not_applicable11 (55%)
Not Specified3 (15%)
Phase 13 (15%)
Phase 22 (10%)
Phase 41 (5%)